Supplementary Tables 1-10 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma
Authors:Helen D. Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen et al.
Supplementary Table S2 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
Marie-Anne Goyette, Christopher Graser et al. - Unknown
Supplementary Table S6 from <i>Helicobacter pylori</i> Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis
Supplementary Figure S4 from <i>SPEN</i> Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Supplementary Data S1 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
Marie-Anne Goyette, Christopher Graser et al. - Unknown